



## CAROLINE PLETT

Medical Doctor  
Psychiatry Resident  
Clinical Scientist

### CONTACT:



Caroline.Plett@med.uni-muenchen.de



Hospital of the University of Munich

Clinic for Psychiatry and  
Psychotherapy Nussbaumstraße 7

80336 München

### PROFILE

---

I am a second-year resident in psychiatry and joined the Lab of Prof. Koutsouleris in October 2021. As a full-time research assistant I am interested in the topic of suicidality and its predictors in young psychotic patients.

Additionally I am dedicated to clinical care in the field of early psychosis including diagnosis and treatment of children and young adults who are both at clinical high risk for psychotic and affective disorders.

After my graduation at the LMU, I worked as a research assistant at the Institute of Medical education and worked on projects related to decision making processes and interprofessional collaboration of clinical teams. Using that experience my goal is to create the curriculum of Artificial Intelligence in medicine for the new chair of precision psychiatry.

### PUBLICATIONS

---

- C. Plett. Immunomodulatory kits generating leukemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia, *Clinical Immunology*, 2021. Review.
- C. Plett, D. C. Amberger, A. Rabe, D. Deen, Z. Stankova, A. Hirn, Y. Vokac, J. Werner, D. Krämer, A. Rank, C. Schmid, H.M. Schmetzer: Immunomodulatory Kits do not induce AML-blasts' proliferation ex vivo. IPO-38 is an appropriate and reliable marker to detect and quantify proliferating blasts. *ITOC 2017 J. ImmunoTherapy of Cancer*, 5 (1), 3-4 (2017)
- D.C. Amberger, F. Doraneh-Gard, C.L. Boeck, C. Plett, C. Gunsilius, C. Kugler, J. Werner, J. Schmohl, D.Kraemer, B. Ismann, A. Rank, C. Schmid, H.M. Schmetzer: A new method to generate mature (leukemia derived) dendritic cells that improve antileukemic T-cell reactivity from mononuclear cells or whole blood from healthy volunteers or patients with AML. *ITOC 2017 J., ImmunoTherapy of Cancer* 5 (1), 4-5 (2017)